Skip to content
Screener

Vaxcyte, Inc. PCVX Retained Earnings

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
Merck & Co. logo
Merck & Co.MRK
$66.72B+0.9%
Moderna logo
ModernaMRNA
$5.1B-38.2%
Novavax logo
NovavaxNVAX
-$4.63B-5.7%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$80.1M+155%
Regenxbio logo
RegenxbioRGNX
-$1.19B-19.7%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017
Line itemMarch 31,2026December 31, 2025
Stockholders' Equity
Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively147134
Additional paid-in capital5,478,2704,838,736
Accumulated other comprehensive loss(6,834)1,587
Accumulated deficit(2,475,569)(2,154,947)
Total stockholders' equity2,996,0142,685,510
Total liabilities and stockholders' equity$3,348,308$3,002,717

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s retained earnings?
Vaxcyte, Inc. (PCVX) reported retained earnings of -$2.48B in Q1 2026.
How has Vaxcyte, Inc.'s retained earnings changed year-over-year?
Vaxcyte, Inc.'s retained earnings decreased by 61.9% year-over-year, from -$1.53B to -$2.48B.
What is the long-term trend for Vaxcyte, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s retained earnings has grown at a 61.1% compound annual growth rate (CAGR), from -$198.56M to -$2.15B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Vaxcyte, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude